Echocardiographic and renal changes in oncologic patients at risk of CTR-CVT treated with SGLT2 inhibitors: a paired 6-month follow-up analysis
6-month longitudinal analysis of oncologic patients at high risk of CTR-CVT, inclusion of SGLT2 inhibitors in a cardioprotective regimen was not associated with adverse cardiac effects and trends toward more stable cardiac and renal parameters were observed, supporting further investigation of SGLT2 inhibitors in cardi...